48.78
price down icon3.35%   -1.69
after-market After Hours: 48.78
loading
Avidity Biosciences Inc stock is traded at $48.78, with a volume of 1.72M. It is down -3.35% in the last 24 hours and up +17.71% over the past month. Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$50.47
Open:
$51.09
24h Volume:
1.72M
Relative Volume:
0.57
Market Cap:
$7.12B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-13.71
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
-3.92%
1M Performance:
+17.71%
6M Performance:
+89.36%
1Y Performance:
-0.33%
1-Day Range:
Value
$48.21
$51.79
1-Week Range:
Value
$46.75
$52.17
52-Week Range:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Name
Avidity Biosciences Inc
Name
Phone
858-401-7900
Name
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
391
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
48.78 7.02B 10.73M -455.74M -502.70M -3.5569
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.61 105.69B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.07 61.52B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
569.17 60.69B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
837.28 50.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.02 35.25B 4.56B -176.77M 225.30M -1.7177

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Roth Capital Buy
Jul-10-25 Resumed Goldman Buy
Jun-24-25 Initiated Bernstein Outperform
Jun-17-25 Initiated Wolfe Research Outperform
Jun-11-25 Initiated Raymond James Strong Buy
Mar-13-25 Initiated Citigroup Buy
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-20-24 Initiated H.C. Wainwright Buy
Nov-26-24 Initiated RBC Capital Mkts Outperform
Sep-24-24 Initiated Goldman Buy
Aug-28-24 Initiated Barclays Overweight
May-03-24 Initiated BofA Securities Buy
Mar-14-24 Initiated Cantor Fitzgerald Overweight
May-22-23 Upgrade Evercore ISI In-line → Outperform
Mar-31-23 Downgrade Evercore ISI Outperform → In-line
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Strong Buy
Sep-07-21 Initiated Evercore ISI Outperform
Jun-17-21 Initiated Needham Buy
Apr-26-21 Resumed Credit Suisse Outperform
Jul-07-20 Initiated Cowen Outperform
Jul-07-20 Initiated Credit Suisse Outperform
Jul-07-20 Initiated SVB Leerink Outperform
Jul-07-20 Initiated Wells Fargo Overweight
View All

Avidity Biosciences Inc Stock (RNA) Latest News

pulisher
Oct 15, 2025

Sector ETF performance correlation with Avidity Biosciences Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How Avidity Biosciences Inc. stock performs in weak economy2025 Biggest Moves & AI Driven Stock Reports - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Forecasting Avidity Biosciences Inc. price range with options data2025 EndofYear Setup & High Return Stock Watch Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

What momentum shifts mean for Avidity Biosciences Inc.Recession Risk & Verified Chart Pattern Trade Signals - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Using R and stats models for Avidity Biosciences Inc. forecasting2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Avidity Biosciences Delays Biologics License Application - TipRanks

Oct 14, 2025
pulisher
Oct 14, 2025

Avidity Biosciences Updates BLA Submission Timeline for Del-Zota - TradingView

Oct 14, 2025
pulisher
Oct 14, 2025

Will a bounce in Avidity Biosciences Inc. offer an exitWeekly Trade Summary & Weekly Hot Stock Watchlists - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Avidity Biosciences delays DMD drug submission to Q1 2026 By Investing.com - Investing.com Nigeria

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - Seeking Alpha

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44 - MarketScreener

Oct 13, 2025
pulisher
Oct 13, 2025

Can Avidity Biosciences Inc. stock beat market expectations this quarterMarket Growth Review & Verified Technical Trade Signals - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Q1 2026 BLA Planned: Avidity's Breakthrough Therapy del‑zota Receives Positive FDA Pre‑BLA Guidance - Stock Titan

Oct 13, 2025
pulisher
Oct 13, 2025

How Avidity Biosciences Inc. stock compares to growth peersQuarterly Profit Review & Safe Entry Trade Reports - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

What Makes Avidity Biosciences (RNA) an Investment Choice? - Yahoo Finance

Oct 13, 2025
pulisher
Oct 13, 2025

Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews

Oct 13, 2025
pulisher
Oct 12, 2025

Chart based exit strategy for Avidity Biosciences Inc.Market Growth Review & Low Risk Entry Point Tips - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Avidity Biosciences Inc. stock daily chart insightsGap Down & Weekly Top Performers Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can Avidity Biosciences Inc. stock hit record highs againPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Avidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Ranking Avidity Biosciences Inc. among high performing stocks via toolsWeekly Stock Recap & Weekly High Momentum Picks - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Is Avidity Biosciences Inc a good long term investmentMid Cap Growth Trends & Low Entry Capital Stocks - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

What drives Ball Corporation stock priceBlue Chip Stock Analysis & High Return Trading Portfolio - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment - TipRanks

Oct 08, 2025
pulisher
Oct 07, 2025

Avidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 Shares - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - BioSpace

Oct 07, 2025
pulisher
Oct 06, 2025

Avidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price Momentum - Yahoo Finance

Oct 06, 2025
pulisher
Oct 06, 2025

Avidity Poised For Commercialization Transformation - San Diego Business Journal

Oct 06, 2025
pulisher
Oct 06, 2025

Quantitative breakdown of Avidity Biosciences Inc. recent move2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Avidity Biosciences Inc. stock trendline breakdownPortfolio Value Report & Free Weekly Watchlist of Top Performers - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Avidity Biosciences Inc Stock Analysis and ForecastStock Price Targets & 5 Stocks Every Investor Should Own - earlytimes.in

Oct 05, 2025
pulisher
Oct 05, 2025

Combining machine learning predictions for Avidity Biosciences Inc.Buy Signal & Fast Moving Stock Watchlists - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Relative strength of Avidity Biosciences Inc. in sector analysisJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Avidity Biosciences Stock Price, Quotes and Forecasts | NASDAQ:RNA - Benzinga

Oct 03, 2025
pulisher
Oct 03, 2025

BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

Can Avidity Biosciences Inc. hit a new high this monthEarnings Summary Report & Weekly Market Pulse Updates - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Real time scanner hits for Avidity Biosciences Inc. explainedBull Run & Technical Entry and Exit Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Is Avidity Biosciences Inc. building a consolidation baseJuly 2025 Catalysts & Weekly Breakout Stock Alerts - newser.com

Oct 03, 2025

Avidity Biosciences Inc Stock (RNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Avidity Biosciences Inc Stock (RNA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mosbrooker Eric
Chief Commercial Officer
Oct 03 '25
Sale
45.38
6,562
297,771
55,000
Hughes Steven George
Chief Medical Officer
Sep 22 '25
Option Exercise
10.16
2,208
22,433
41,075
Hughes Steven George
Chief Medical Officer
Sep 22 '25
Sale
40.58
2,208
89,601
38,867
McCarthy Teresa
Chief Human Resources Officer
Sep 15 '25
Option Exercise
22.34
15,000
335,100
112,130
McCarthy Teresa
Chief Human Resources Officer
Sep 15 '25
Sale
41.41
15,000
621,142
97,130
Hughes Steven George
Chief Medical Officer
Sep 15 '25
Option Exercise
6.57
1,542
10,131
40,409
Hughes Steven George
Chief Medical Officer
Sep 15 '25
Sale
45.41
1,542
70,022
38,867
Flanagan W. Michael
Chief Scientific Officer
Sep 11 '25
Option Exercise
14.22
20,000
284,400
100,195
Flanagan W. Michael
Chief Scientific Officer
Sep 11 '25
Sale
38.94
20,000
778,702
80,195
$21.97
price down icon 2.96%
$87.31
price down icon 0.95%
$32.75
price up icon 0.09%
$105.08
price up icon 0.71%
$163.19
price down icon 0.21%
biotechnology ONC
$318.02
price up icon 0.59%
Cap:     |  Volume (24h):